STAAR Surgical (STAA) Tops Q4 EPS by 4c
Get Alerts STAA Hot Sheet
Price: $24.16 +2.94%
Revenue Growth %: -16.5%
Financial Fact:
Interest income: 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -16.5%
Financial Fact:
Interest income: 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
STAAR Surgical (NASDAQ: STAA) reported Q4 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $22.06 million.
Fourth Quarter 2016 Overview
- Record Quarterly Net Sales of $22.1 Million Up 6% from the Prior Year Quarter
- Record Quarter for ICL Sales Up 11% and Units Up 10% from the Prior Year Quarter
- IOL Sales Flat and Units Up 5% from the Prior Year Quarter
- Gross Margin Improved to 71.7% of Sales from 70.3% of Sales in the Prior Year Quarter
- On-Going FDA Remediation Effort Finished the Quarter On-Track and On-Budget
- Fourth Quarter Breakeven per Share; Adjusted Net Income of $0.02 per Share
- Cash and Equivalents Ended the Quarter at $14.0 Million.
For earnings history and earnings-related data on STAAR Surgical (STAA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share